Abstract
NAFLD is emerging as one of the commonest causes of abnormal liver function tests, and in the Western world the estimated prevalence is reported to be as high as 30%.1 The prevalence of NAFLD is expected to rise in developed countries given the epidemic of its major underlying determinant obesity, in addition to the increasing ascertainment of this condition. Histologically, NAFLD is a spectrum of disease from simple fatty deposition (steatosis), to necroinflammation in zone 3 in association with ballooning degeneration (non-alcoholic steatohepatitis (NASH)), to periportal and/or perisinusoidal fibrosis, to cirrhosis. The natural history is varied; at the early stages of disease the majority remain stable at the same histological stage and grade, a proportion however will progress to cirrhosis (there is variation in the rate of progression), and finally some will have regression of disease.

This publication has 54 references indexed in Scilit: